Compare Gogoro Inc (GGR) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Gogoro Inc. (GGR) trades at $3.86, up 1.58% on the day, but remains in a technically bearish trend. Fundamentally, the company reported Q1 2026 results highlighting improved margins and positive operating cash flow, though it continues to post significant net losses with a -24.68% net income margin. The analyst consensus is unanimously neutral with a 100% Hold rating, reflecting caution despite recent operational progress.

The outlook is mixed. Opportunities stem from Gogoro's growing battery-swapping subscriber base and expansion into new markets like Vietnam. However, significant risks persist, including sustained unprofitability, high cash burn with a net cash flow of -$46.57M in 2025, and negative shareholder returns evidenced by a -50.38% ROE. The stock's low P/S of 0.21 suggests the market has heavily discounted its growth prospects.

IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.

Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.